Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 8, 1997, Pages 1709-1714

  Polis, Michael A ^a   Piscitelli, Stephen C ^b   Vogel, Susan ^a   Witebsky, Frank G ^b   Conville, Patricia S ^b   Petty, Brent ^c   Kovacs, Joseph A ^b   Davey Jr , Richard T ^a   Walker, Robert E ^a   Falloon, Judith ^a   Metcalf, Julia A ^a   Craft, Carl ^d   Lane, H Clifford ^a   Masur, Henry ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CLARITHROMYCIN; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; HEARING LOSS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MENTAL DISEASE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH;

EID: 0030872455     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.8.1709     Document Type: Article

References (19)

1. Chaisson, R. E., C. A. Benson, M. P. Dube, L. B. Heifets, J. A. Korvick, S. Elkin, T. Smith, J. C. Craft, F. R. Sattler, and the ACTG Protocol 157 Study Team. 1994. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease in patients with AIDS. Ann. Intern. Med. 121:905-911.
2. Chu, S., D. S. Wilson, R. L. Deaton, A. V. MacKenthon, C. N. Eason, and J. H. Cavanaugh. 1993. Single-and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J. Clin. Pharmacol. 33:719-726.
3. Chu, S. Y., L. T. Sennello, and R. C. Sonders. 1991. Simultaneous determination of clarithromycin and 14(R)-hydroxyclarithromycin in plasma and urine using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. 571:199-208.
4. D'Argenio, D. Z., and A. Schumitzky. 1992. ADAPT II users guide. Biomedical Simulations Resource, University of Southern California, Los Angeles, Calif.
5. Dautzenberg, B., T. Saint Marc, M. C. Meyohas, M. Eliaszewitch, F. Haniez, A. M. Rogues, and S. De Wit. 1993. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with the acquired immunodeficiency syndrome. Arch. Intern. Med. 153:363-372.
6. Dautzenberg, B., C. Truffot, S. Legris, M. Meyhohas, H. C. Berlie, A. Mercat, S. Chevrat, and J. Grosset. 1991. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immunodeficiency syndrome. Am. Rev. Respir. Dis. 144:564-569.
7. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed. Marcel Dekker, New York, N.Y.
8. Goldberger, M., and H. Masur. 1994. Clarithromycin therapy for Mycobacterium avium complex disease in patients with AIDS: potential and problems. Ann. Intern. Med. 121:974-976.
9. Heifets, L., N. Mor, and J. Vanderkolk. 1993. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob. Agents Chemother. 37:2364-2370.
10. Ishiguro, M., H. Koga, S. Hohno, T. Hayashi, K. Yamaguchi, and M. Hirota. 1989. Penetration of macrolides into human polymorphonuclear leucocytes. J. Antimicrob. Chemother. 24:719-729.
11. Narang, P., S. Nightingale, C. Manzone, D. Colborn, B. Wynne, R. Li, D. Watson, N. Barris, T. Blaschke, and J. R. Bianchine. 1992. Does rifabutin (RIF) affect zidovudine (ZDV) disposition in HIV (+) patients? abstr. PoB 3888, p. B239. In Poster abstracts of the VIII International Conference on AIDS. CONGREX Holland B.V., Amsterdam, The Netherlands.
12. National Committee for Clinical Laboratory Standards. 1990. Antimycobacterial susceptibility testing. Proposed standard. Document M24-P. National Committee for Clinical Laboratory Standards, Villanova, Pa.
13. National Institute of Allergy and Infectious Diseases. 1996. A note to physicians: important therapeutic information on the dosing of clarithromycin for the treatment of disseminated Mycobacterium avium complex (DMAC) infection in HIV-infected patients. National Institutes of Health, Bethesda, Md.
14. Petty, B., M. Polis, S. Haneiwich, M. Dellerson, J. C. Craft, and R. Chaisson. 1992. Pharmacokinetic assessment of clarithromycin plus zidovudine in HIV patients, abstr. 24, p. 114. In Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society of Microbiology, Washington, D.C.
15. Pierce, M., S. Crampton, D. Henry, L. Heifets, A. LaMarca, M. Montecalvo, G. P. Wormser, H. Jablonowski, J. Jemsek, M. Cynamon, B. G. Yangco, G. Notario, and J. C. Craft. 1996. A randomized trial of clarithromycin as prophylaxis against Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N. Engl. J. Med. 335:384-391.
16. Shafran, S. D., J. Singer, D. P. Zarowny, P. Phillips, I. Salit, S. L. Walmsley, I. W. Fong, M. J. Gill, A. R. Rachlis, R. G. Lalonde, M. M. Fanning, C. M. Tsoukas, lor the Canadian HIV Trials Network Protocol 010 Study Group. 1996. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N. Engl. J. Med. 335:377-383.
17. Vance, E., M. Watson-Bitar, L. Gustavson, and P. Kazanjian. 1995. Pharmacokinotics of clarithromycin and zidovudine in patients with AIDS. Antimicrob. Agents Chemother. 39:1355-1360.
18. Wallace, R. J., Jr., B. A. Brown, D. E. Griffith, W. Girard, and K. Tanaka. 1995. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J. Infect. Dis. 171:747-750.
19. Yamaoka, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175.